Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Colorcon
Moodys
AstraZeneca
Boehringer Ingelheim

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,774,122

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,774,122 protect, and when does it expire?

Patent 6,774,122 protects FASLODEX and is included in one NDA.

Protection for FASLODEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-one patent family members in forty countries.

Summary for Patent: 6,774,122
Title: Formulation
Abstract:The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-t riene-3,17.beta.-diol, more particularly to a formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-t riene-3,17.beta.-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
Inventor(s): Evans; John R (Macclesfield, GB), Grundy; Rosalind U (Macclesfield, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:09/756,291
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,774,122
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 6,774,122

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 AO RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,774,122

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0000313Jan 10, 2000
United Kingdom0008837Apr 12, 2000

International Family Members for US Patent 6,774,122

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 027510   Start Trial
Austria 306928   Start Trial
Australia 2386301   Start Trial
Australia 762080   Start Trial
Belgium 1013477   Start Trial
Bulgaria 106833   Start Trial
Bulgaria 65776   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Dow
Merck
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.